Danaher Free Cash Flow 2010-2025 | DHR
Danaher annual/quarterly free cash flow history and growth rate from 2010 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Danaher free cash flow for the quarter ending March 31, 2025 was 1,060.00, a year-over-year.
- Danaher free cash flow for the twelve months ending March 31, 2025 was , a year-over-year.
- Danaher annual free cash flow for 2024 was $5.309B, a 8.35% decline from 2023.
- Danaher annual free cash flow for 2023 was $5.793B, a 21.82% decline from 2022.
- Danaher annual free cash flow for 2022 was $7.41B, a 3.91% increase from 2021.
| Danaher Annual Free Cash Flow | |
|---|---|
| 2024 | 5,309.00 |
| 2023 | 5,793.00 |
| 2022 | 7,410.00 |
| 2021 | 7,131.00 |
| 2020 | 5,419.00 |
| 2019 | 3,329.00 |
| 2018 | 3,444.00 |
| 2017 | 2,939.60 |
| 2016 | 2,942.00 |
| 2015 | 3,349.30 |
| 2014 | 3,293.00 |
| 2013 | 3,047.20 |
| 2012 | 2,956.70 |
| 2011 | 2,291.80 |
| 2010 | 1,894.90 |
| 2009 | 1,630.41 |
| Danaher Quarterly Free Cash Flow | |
|---|---|
| 2025-03-31 | 1,060.00 |
| 2024-12-31 | 5,309.00 |
| 2024-09-30 | 3,805.00 |
| 2024-06-30 | 2,579.00 |
| 2024-03-31 | 1,448.00 |
| 2023-12-31 | 5,793.00 |
| 2023-09-30 | 4,602.00 |
| 2023-06-30 | 3,280.00 |
| 2023-03-31 | 1,681.00 |
| 2022-12-31 | 7,410.00 |
| 2022-09-30 | 5,164.00 |
| 2022-06-30 | 3,431.00 |
| 2022-03-31 | 1,720.00 |
| 2021-12-31 | 7,131.00 |
| 2021-09-30 | 5,164.00 |
| 2021-06-30 | 3,448.00 |
| 2021-03-31 | 1,632.00 |
| 2020-12-31 | 5,419.00 |
| 2020-09-30 | 3,513.00 |
| 2020-06-30 | 1,977.00 |
| 2020-03-31 | 687.00 |
| 2019-12-31 | 3,329.00 |
| 2019-09-30 | 2,396.40 |
| 2019-06-30 | 1,592.10 |
| 2019-03-31 | 563.70 |
| 2018-12-31 | 3,444.00 |
| 2018-09-30 | 2,344.70 |
| 2018-06-30 | 1,574.60 |
| 2018-03-31 | 691.40 |
| 2017-12-31 | 2,939.60 |
| 2017-09-30 | 2,229.60 |
| 2017-06-30 | 1,294.20 |
| 2017-03-31 | 402.30 |
| 2016-12-31 | 2,942.00 |
| 2016-09-30 | 2,457.90 |
| 2016-06-30 | 1,786.30 |
| 2016-03-31 | 650.20 |
| 2015-12-31 | 3,349.30 |
| 2015-09-30 | 2,218.60 |
| 2015-06-30 | 1,364.40 |
| 2015-03-31 | 406.60 |
| 2014-12-31 | 3,293.00 |
| 2014-09-30 | 2,109.70 |
| 2014-06-30 | 1,224.30 |
| 2014-03-31 | 380.30 |
| 2013-12-31 | 3,047.20 |
| 2013-09-30 | 2,115.30 |
| 2013-06-30 | 1,283.20 |
| 2013-03-31 | 520.20 |
| 2012-12-31 | 2,956.70 |
| 2012-09-30 | 2,281.90 |
| 2012-06-30 | 1,425.60 |
| 2012-03-31 | 527.50 |
| 2011-12-31 | 2,291.80 |
| 2011-09-30 | 1,594.54 |
| 2011-06-30 | 997.46 |
| 2011-03-31 | 392.59 |
| 2010-12-31 | 1,894.90 |
| 2010-09-30 | 1,371.60 |
| 2010-06-30 | 843.31 |
| 2010-03-31 | 356.93 |
| 2009-12-31 | 1,630.41 |
| 2009-09-30 | 1,193.47 |
| 2009-06-30 | 720.57 |
| 2009-03-31 | 280.61 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $138.189B | $23.875B |
| Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $94.312B | 12.17 |
| CVS Health (CVS) | United States | $84.478B | 10.50 |
| Cencora (COR) | United States | $59.063B | 20.54 |
| Natera (NTRA) | United States | $21.643B | 0.00 |
| DiDi Global (DIDIY) | China | $20.379B | 30.93 |
| BioMerieux (BMXMF) | France | $15.263B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.707B | 0.00 |
| Solventum (SOLV) | United States | $11.330B | 10.56 |
| ICON (ICLR) | Ireland | $11.213B | 10.42 |
| CochLear (CHEOY) | Australia | $11.158B | 0.00 |
| Doximity (DOCS) | United States | $10.895B | 56.66 |
| Revvity (RVTY) | United States | $10.796B | 18.58 |
| Viatris (VTRS) | United States | $10.198B | 3.25 |
| Medpace Holdings (MEDP) | United States | $8.622B | 22.90 |
| Sonic Healthcare (SKHHY) | Australia | $8.157B | 0.00 |
| Avantor (AVTR) | United States | $8.136B | 11.82 |
| HealthEquity (HQY) | United States | $7.933B | 39.03 |
| Charles River Laboratories (CRL) | United States | $6.727B | 13.18 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| Bausch + Lomb (BLCO) | Canada | $4.028B | 23.75 |
| BrightSpring Health Services (BTSG) | United States | $4.015B | 37.16 |
| Sotera Health (SHC) | United States | $3.733B | 21.21 |
| Alignment Healthcare (ALHC) | United States | $3.071B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.969B | 34.06 |
| Concentras Parent (CON) | United States | $2.803B | 16.20 |
| Organon (OGN) | United States | $2.277B | 2.42 |
| Premier (PINC) | United States | $2.111B | 14.45 |
| Ardent Health Partners (ARDT) | United States | $2.028B | 8.66 |
| Progyny (PGNY) | United States | $2.006B | 44.19 |
| GeneDx Holdings (WGS) | United States | $1.609B | 63.01 |
| PACS (PACS) | United States | $1.603B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.454B | 27.07 |
| Agilon Health (AGL) | United States | $1.403B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.233B | 9.38 |
| Teladoc Health (TDOC) | United States | $1.203B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.039B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.960B | 0.00 | |
| CareDx (CDNA) | United States | $0.822B | 12.84 |
| AMN Healthcare Services Inc (AMN) | United States | $0.749B | 5.92 |
| Embecta (EMBC) | United States | $0.725B | 4.97 |
| QDM (QDMI) | Hong Kong, SAR China | $0.671B | 0.00 |
| Nutex Health (NUTX) | United States | $0.649B | 12.72 |
| Auna S.A (AUNA) | Luxembourg | $0.518B | 13.73 |
| Sonida Senior Living (SNDA) | United States | $0.452B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.440B | 0.00 |
| Enhabit (EHAB) | United States | $0.415B | 34.17 |
| LifeMD (LFMD) | United States | $0.364B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.347B | 0.00 |
| SBC Medicals (SBC) | United States | $0.332B | 0.00 |
| DocGo (DCGO) | United States | $0.245B | 10.00 |
| Oncology Institute (TOI) | United States | $0.208B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.179B | 0.00 |
| Beauty Health (SKIN) | United States | $0.178B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.090B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.087B | 0.00 |
| So-Young (SY) | China | $0.084B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.084B | 0.00 |
| OncoCyte (OCX) | United States | $0.081B | 0.00 |
| Biodesix (BDSX) | United States | $0.062B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.029B | 0.00 |
| ModivCare (MODV) | United States | $0.019B | 6.75 |
| KindlyMD (KDLY) | United States | $0.019B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |